Vitrolife: Interim report Q3, 2026: Improved growth driven by Technologies

By Modular Finance

Third quarter

  • Sales of SEK 884 (835) million, an organic growth of 6% in local currencies, excluding the exited NACE and GPDx product lines. Total growth was 4% in local currencies and 6% in SEK.
  • Sales* per region were +11% in EMEA, +5% in Americas and +2% in APAC.
  • Sales* per product group were +1% in Consumables, +21% in Technologies and +5% in Genetics.
  • Gross margin increased to 59.2% (58.9).
  • Earnings before depreciation and amortisation (EBITDA) amounted to SEK 279 (253) million, resulting in an EBITDA margin of 31.6% (30.3).
  • Net income amounted to SEK 124 (102) million, resulting in earnings per share, before and after dilution, of SEK 0.94 (0.75).
  • Operating cash flow amounted to SEK 224 (255) million.
  • Repurchase of own shares of SEK 246 million under the SEK 500 million programme.

First nine months

  • Sales of SEK 2,548 (2,548) million, a growth of 3% in local currencies and flat in SEK, due to a negative currency impact of -3%. Organic growth* was 4%.
  • Sales* per region were +4% in EMEA, +6% in Americas and +3% in APAC.
  • Sales* per product group were +4% in Consumables, +11% in Technologies and +1% in Genetics.
  • Gross margin increased to 59.8% (58.1).
  • Earnings before depreciation and amortisation (EBITDA) increased to SEK 825 (753) million, resulting in an EBITDA margin of 32.4% (29.5).
  • Net income was SEK 354 (301) million, resulting in earnings per share, before and after dilution, of SEK 2.64 (2.23).
  • Operating cash flow amounted to SEK 536 million (475).

* In local currency and excluding exited business of the NACE and GPDx product lines

Contact:
Cecilia Möllerstrandh
Investor Relations
investors@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About Us
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden.
Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

This information is information that Vitrolife is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-10-22 08:00 CEST.

Attachments
Interim Report Q3 2026

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.